FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

CIPLA

655
-5.55 (-0.84%)
Updated 03:29 05/06 IST

CIPLA Buy or Sell - FrontPage Forums

3 Users have submitted 3 trade ideas of Rs. 1,350,227.03 for CIPLA
Disclaimer
100% Bullish
0% Bearish

CIPLA Ratings

Long term CIPLA rating by FrontPage users
3.8/5 (16 Ratings)
Find answers to all your questions on live CIPLA message board: Is CIPLA buy or sell? Should I buy CIPLA shares? Why are CIPLA shares falling? Should I invest in CIPLA stock?

CIPLA Share Price Discussion

Bulls vs Bears in CIPLA
#CIPLA There's a deviation in the channel afte...
Like
Reply
Reputation: 3,179 • Today 7:48 AM
Monsoon to bring relief amid COVID-19 pain; 9 stocks that could benefit
Experts point out that the rabi season ended largely on expected lines and at present, it appears the Kharif crop is unlikely to be affected and may see a normal season.
Moneycontrol
Like
Reply
M
Reputation: 10,911 • Today 5:44 AM

Type
Buy
Instrument
CIPLA JUN20 FUT
Entry Price
₹657.35
Price@Trade
₹657.35
Target Price
₹695
Stop Price
₹638
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹178,385.34 approx for 1150 Qty
Status
Active
Like
Reply
Reputation: 3,179 • Today 4:51 AM
Share market update: 29 stocks hit 52-week highs on NSE
​Benchmark NSE Nifty index was trading 43.80 points up at 10072.90.
The Economic Times
1
Reply
S
Reputation: -36 • Today 3:24 AM

Type
Buy
Instrument
CIPLA
Entry Price
₹664
Price@Trade
₹663.9
Target Price
₹679
Stop Price
₹659
Valid Till
Jun 5, 2020 3:20 AM
Margin
₹199,200 approx for 300 Qty
Status
Exited
Exit Price
₹659.85
Net P&L
-₹1,245 (-0.63%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Today 3:25 AM

Update
Trade Entered
Entry Price
₹664
Sahil Shukla @338158
Today 3:54 AM

Update
Exited
Exit Price
₹659.85
Net P&L
-₹1,245 (-0.63%)
Reputation: 2,933 • Today 3:21 AM

Type
Buy
Instrument
CIPLA
Entry Price
₹662
Price@Trade
₹662
Target Price
₹675
Stop Price
₹650
Valid Till
Jun 5, 2020 3:20 AM
Margin
₹132,400 approx for 200 Qty
Status
Exited
Exit Price
₹651.15
Net P&L
-₹2,170 (-1.64%)
Like
Reply (1)
Latest replies
Trading Calls @tradingcalls
Today 8:31 AM

Update
Exited
Exit Price
₹651.15
Net P&L
-₹2,170 (-1.64%)
N
Reputation: 5,564 • Today 2:55 AM

Type
Sell
Instrument
CIPLA JUN20 FUT
Entry Price
₹663
Price@Trade
₹662.5
Target Price
₹655
Stop Price
₹667.55
Valid Till
Jun 5, 2020 3:20 AM
Margin
₹178,927.92 approx for 1150 Qty
Status
Exited
Exit Price
₹656.55
Net P&L
+₹7,417.5 (+4.15%)
1
Reply (2)
Latest replies
TrackerBot @trackerbot
Today 2:56 AM

Update
Trade Entered
Entry Price
₹663
Neeraj @neeraj-B1_n_gdHr
Today 3:12 AM

Update
Exited
Exit Price
₹656.55
Net P&L
+₹7,417.5 (+4.15%)
Bulls vs Bears in CIPLA
#CIPLA Pattern to watch

CIPLA - 864324
#CIPLA There's a deviation in the channel after a minor breakdown.
Like
Reply

Type
Buy
Instrument
CIPLA
Entry Price
₹658.95
Price@Trade
₹658.95
Target Price
₹668
Stop Price
₹653
Valid Till
Jun 5, 2020 3:20 AM
Margin
₹197,685 approx for 300 Qty
Status
Exited
Exit Price
₹666.95
Net P&L
+₹2,400 (+1.21%)
Like
Reply (1)
Latest replies
Trading Calls @tradingcalls
Today 2:46 AM

Update
Exited
Exit Price
₹666.95
Net P&L
+₹2,400 (+1.21%)
Reputation: -265 • Yesterday 8:04 AM

Type
Buy
Instrument
CIPLA JUN20 650 CE
Entry Price
₹30.4
Price@Trade
₹30.4
Target Price
₹40
Stop Price
₹25
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹69,920 approx for 2300 Qty
Status
Exited
Exit Price
₹30.85
Net P&L
+₹1,035 (+1.48%)
Like
Reply (1)
Latest replies
kalyan @kalyanm
Yesterday 8:27 AM

Update
Exited
Exit Price
₹30.85
Net P&L
+₹1,035 (+1.48%)

Type
Buy
Instrument
CIPLA JUN20 FUT
Entry Price
₹657.6
Price@Trade
₹657.6
Target Price
₹700
Stop Price
₹640
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹176,796.4 approx for 1150 Qty
Status
Exited
Exit Price
₹663
Net P&L
+₹6,210 (+3.51%)
Like
Reply (1)
Latest replies

Update
Exited
Exit Price
₹663
Net P&L
+₹6,210 (+3.51%)
Reputation: 3,179 • Yesterday 5:51 AM
Share market update: Pharma shares up; Lupin rises over 2%
The Nifty Pharma index was trading 1.11 per cent up at 9973.95.
The Economic Times
Like
Reply
Reputation: 3,179 • Yesterday 4:41 AM
Share market update: 20 stocks hit 52-week highs on NSE
The BSE Sensex was trading 52.72 points down at 34056.82.
The Economic Times
Like
Reply

Type
Sell
Instrument
CIPLA
Entry Price
₹655
Price@Trade
₹658.6
Target Price
₹640
Stop Price
₹662
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹655,000 approx for 1000 Qty
Status
Exited
Exit Price
₹651.25
Net P&L
+₹3,750 (+0.57%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Yesterday 4:39 AM

Update
Trade Entered
Entry Price
₹655
Ashish Paswan @tradingwithashish
Yesterday 5:00 AM

Update
Exited
Exit Price
₹651.25
Net P&L
+₹3,750 (+0.57%)

Type
Sell
Instrument
CIPLA
Entry Price
₹657
Price@Trade
₹656.65
Target Price
₹648
Stop Price
₹662
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹197,100 approx for 300 Qty
Status
Target Achieved
Exit Price
₹648
Net P&L
+₹2,700 (+1.37%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Yesterday 4:09 AM

Update
Trade Entered
Entry Price
₹657
TrackerBot @trackerbot
Yesterday 5:28 AM

Update
Target Achieved
Exit Price
₹648

Type
Buy
Instrument
CIPLA JUN20 FUT
Entry Price
₹659
Price@Trade
₹659
Target Price
₹680
Stop Price
₹643
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹174,416.69 approx for 1150 Qty
Status
Active
Like
Reply
Reputation: 462 • Yesterday 3:05 AM

Type
Sell
Instrument
CIPLA
Entry Price
₹652
Price@Trade
₹652
Target Price
₹643
Stop Price
₹655
Valid Till
Jun 4, 2020 3:20 AM
Margin
₹652,000 approx for 1000 Qty
Status
Stoploss Hit
Exit Price
₹655
Net P&L
-₹3,000 (-0.46%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Yesterday 3:34 AM

Update
Stoploss Hit
Exit Price
₹655
Reputation: 3,179 • Yesterday 2:01 AM
Indian licensees free to price Remdesivir: Gilead
US drug maker to launch own brand of Covid-19 experimental drug in the country next month. Gilead has licensed the drug to four companies — Cipla, Mylan, Hetero and Jubilant Life Sciences — for sale in India, but none of these firms has received approval from the drug controller. most of the four companies are ready with their products and are awaiting nod from the regulator to manufacture and start selling the drug in the country.
The Economic Times
Like
Reply
M
Reputation: 10,911 • Jun 3 7:09 AM

Type
Buy
Instrument
CIPLA JUN20 FUT
Entry Price
₹645.25
Price@Trade
₹644.9
Target Price
₹725
Stop Price
₹629
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹174,813.23 approx for 1150 Qty
Status
Exited
Exit Price
₹649
Net P&L
+₹4,312.5 (+2.47%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jun 3 7:10 AM

Update
Trade Entered
Entry Price
₹645.25
Marketguru @marketguru
Yesterday 2:52 AM

Update
Exited
Exit Price
₹649
Net P&L
+₹4,312.5 (+2.47%)
Reputation: 13,291 • Jun 3 6:23 AM

Type
Sell
Instrument
CIPLA
Entry Price
₹642  ₹641.65
Price@Trade
₹641.95
Target Price
₹634
Stop Price
₹647
Valid Till
Jun 4, 2020 3:20 AM  Jun 5, 2020 3:20 AM
Margin
₹128,330 approx for 200 Qty
Status
Stoploss Hit
Exit Price
₹643.1
Net P&L
-₹290 (-0.23%)
Like
Reply (4)
Latest replies
King999 @king999
Jun 3 6:23 AM

Update
Entry Price Modified
Price @ Update
₹641.65
Original Entry Price
₹642
New Entry Price
₹641.65
TrackerBot @trackerbot
Jun 3 6:24 AM

Update
Trade Entered
Entry Price
₹641.65
King999 @king999
Jun 3 6:52 AM

Update
Time Extended
Price @ Update
₹643.4
Original Time
Jun 4, 2020 3:20 AM
New Time
Jun 5, 2020 3:20 AM
TrackerBot @trackerbot
Yesterday 2:46 AM

Update
Stoploss Hit
Exit Price
₹643.1
Reputation: 3,179 • Jun 3 5:51 AM
Share market update: Pharma shares climb; Dr Reddy's Labs gains 2%
The Nifty Pharma index was trading 0.76 per cent up at 9908.5.
The Economic Times
Like
Reply
I
Reputation: -191 • Jun 3 5:15 AM

Type
Sell
Instrument
CIPLA
Entry Price
₹644.9
Price@Trade
₹646
Target Price
₹640
Stop Price
₹645.9
Valid Till
Jun 3, 2020 3:20 AM
Margin
₹322,450 approx for 500 Qty
Status
Exited before entry
Like
Reply (1)
Latest replies
Ishant @ishant-Bk6wkJwSB
Jun 3 5:16 AM

Update
Exited before entry
Price @ Update
₹646
S
Reputation: 1,138 • Jun 3 4:43 AM

Type
Sell
Instrument
CIPLA
Entry Price
₹645
Price@Trade
₹646.3
Target Price
₹638
Stop Price
₹651
Valid Till
Jun 3, 2020 3:20 AM
Margin
₹645,000 approx for 1000 Qty
Status
Exited
Exit Price
₹641
Net P&L
+₹4,000 (+0.62%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jun 3 5:41 AM

Update
Trade Entered
Entry Price
₹645
sumit @sumit-rkGEzkV2L
Jun 3 8:34 AM

Update
Exited
Exit Price
₹641
Net P&L
+₹4,000 (+0.62%)
Reputation: 2,933 • Jun 3 3:42 AM

Type
Buy
Instrument
CIPLA
Entry Price
₹649
Price@Trade
₹648
Target Price
₹658
Stop Price
₹643
Valid Till
Jun 3, 2020 3:20 AM
Margin
₹194,700 approx for 300 Qty
Status
Stoploss Hit
Exit Price
₹643
Net P&L
-₹1,800 (-0.92%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jun 3 3:46 AM

Update
Trade Entered
Entry Price
₹649
TrackerBot @trackerbot
Jun 3 6:14 AM

Update
Stoploss Hit
Exit Price
₹643
Reputation: 2,933 • Jun 3 3:20 AM

Type
Sell
Instrument
CIPLA
Entry Price
₹640
Price@Trade
₹642.3
Target Price
₹635
Stop Price
₹645
Valid Till
Jun 3, 2020 3:20 AM
Margin
₹192,000 approx for 300 Qty
Status
Exited before entry
Like
Reply (1)
Latest replies
Trading Calls @tradingcalls
Jun 3 3:35 AM

Update
Exited before entry
Price @ Update
₹647.9
Reputation: 6,068 • Jun 3 3:19 AM

Type
Buy
Instrument
CIPLA JUN20 FUT
Entry Price
₹644
Price@Trade
₹642.8
Target Price
₹649.8
Stop Price
₹641.2  ₹645
Valid Till
Jun 3, 2020 3:20 AM
Margin
₹173,371.91 approx for 1150 Qty
Status
Target Achieved
Exit Price
₹649.8
Net P&L
+₹6,670 (+3.85%)
buy cipla 644 target 650-656-662 stoploss 641.2
Like
Reply (3)
Latest replies
TrackerBot @trackerbot
Jun 3 3:26 AM

Update
Trade Entered
Entry Price
₹644
SAGAANI @sagaani
Jun 3 3:34 AM

Update
Stoploss Trailed
Price @ Update
₹648.5
Original SL
₹641.2
New SL
₹645
TrackerBot @trackerbot
Jun 3 3:46 AM

Update
Target Achieved
Exit Price
₹649.8
Reputation: 6,068 • Jun 3 3:18 AM

buy cipla 644 target 650-656-662 stoploss 641.2
Like
Reply
Reputation: 5,620 • Jun 2 2:20 AM

Our Darling CPR-ORB Performance:
#MUTHOOTHFIN NOT TRIGGER
SELL #HINDUNILIVER from 2102.60 TO LOW MADE 2101 NO MOVEMENT
BUY #CIPLA from 650.55 TO 658.55💥
SELL #JSWSTEEL from 193.90 TO 190.40
SELL #BHARATFROG from 335.30 TO 332
SELL #IBULHSGFIN from 126.75 TO 124.70
BUY #DMART ...
Read more...
26
Reply (13)
Latest replies
Yash @yash-rkwVuRG2I
Jun 2 4:25 AM
Akash N V @akashnv
Jun 3 1:03 AM

@yash-rkwVuRG2I bro does cpr narrow range breakouts is working well it's profitable???? Please reply
Yash @yash-rkwVuRG2I
Jun 3 2:20 AM

@akashnv half of them work (1.5 RRR) remaining half either hit STL or don't breakout
King Harry @kingharry
Jun 3 2:32 AM

@yash-rkwVuRG2I end of d day hum profit mein hi rehte h......backtest kar lo...... Isliye deta hu jisse aapko confidence aa sake
Yash @yash-rkwVuRG2I
Jun 3 2:36 AM

Yes. That's the logic, not all trades are profitable. You have to accept that and take reasonably assessed technically sound calls.
Harry also has some SRM strategy too to manage trades to remain profitable. I too have my own
DECENT PROFITS in CIPLA
#CIPLA 644.70

637❤❤❤❤❤❤🎯🎯🎯🎯🎯🎯
Like
Reply
Reputation: 19,103 • Jun 2 6:40 AM

Type
Sell
Instrument
CIPLA JUN20 FUT
Entry Price
₹643.55
Price@Trade
₹643.55
Target Price
₹640
Stop Price
₹645.5
Valid Till
Jun 2, 2020 3:20 AM
Margin
₹174,494 approx for 1150 Qty
Status
Exited
Exit Price
₹641.6
Net P&L
+₹2,242.5 (+1.29%)
Like
Reply (1)
Latest replies
ProTrader @ProTraderIndia
Jun 2 6:57 AM

Update
Exited
Exit Price
₹641.6
Net P&L
+₹2,242.5 (+1.29%)
Reputation: 19,103 • Jun 2 4:59 AM

Type
Sell
Instrument
CIPLA JUN20 FUT
Entry Price
₹645.7
Price@Trade
₹645.7
Target Price
₹640
Stop Price
₹648
Valid Till
Jun 2, 2020 3:20 AM
Margin
₹174,581.42 approx for 1150 Qty
Status
Exited
Exit Price
₹646
Net P&L
-₹345 (-0.2%)
Like
Reply (1)
Latest replies
ProTrader @ProTraderIndia
Jun 2 5:12 AM

Update
Exited
Exit Price
₹646
Net P&L
-₹345 (-0.2%)
DECENT PROFITS in CIPLA
#CIPLA 645❤❤❤❤❤
Like
Reply
DECENT PROFITS in CIPLA
#CIPLA 645.95
Like
Reply
DECENT PROFITS in CIPLA
#CIPLA 646.05
Like
Reply
DECENT PROFITS in CIPLA
New trade: Sell CIPLA JUN20 FUT, CMP@646.7, Ent...
Like
Reply

Type
Sell
Instrument
CIPLA JUN20 FUT
Entry Price
₹650  ₹647.5
Price@Trade
₹646.7
Target Price
₹635
Stop Price
₹655
Valid Till
Jun 2, 2020 3:20 AM
Margin
₹174,653.88 approx for 1150 Qty
Status
Exited
Exit Price
₹646.15
Net P&L
+₹1,552.5 (+0.89%)
Like
Reply (4)
Latest replies

Update
Entry Price Modified
Price @ Update
₹647.5
Original Entry Price
₹650
New Entry Price
₹647.5

Update
Entry Price Modified
Price @ Update
₹647.5
Original Entry Price
₹647.5
New Entry Price
₹647.5
TrackerBot @trackerbot
Jun 2 4:36 AM

Update
Trade Entered
Entry Price
₹647.5

Update
Exited
Exit Price
₹646.15
Net P&L
+₹1,552.5 (+0.89%)

Type
Sell
Instrument
CIPLA
Entry Price
₹650.25
Price@Trade
₹650.25
Target Price
₹645
Stop Price
₹653
Valid Till
Jun 2, 2020 3:20 AM
Margin
₹650,250 approx for 1000 Qty
Status
Exited
Exit Price
₹645.95
Net P&L
+₹4,300 (+0.66%)
Like
Reply (1)
Latest replies

Update
Exited
Exit Price
₹645.95
Net P&L
+₹4,300 (+0.66%)
Reputation: 6,068 • Jun 2 3:44 AM

CIPLA - 850901
BUY CIPLA 643.9 TARGET 649.5-656-662.5 STOPLOSS 640.15
2 nd target done - happy trading
profit rs. 12 per share
Like
Reply

Type
Buy
Instrument
CIPLA JUN20 660 CE
Entry Price
₹26
Price@Trade
₹27.25
Target Price
₹28
Stop Price
₹24
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹59,800 approx for 2300 Qty
Status
Stoploss Hit
Exit Price
₹24
Net P&L
-₹4,600 (-7.69%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jun 2 3:32 AM

Update
Trade Entered
Entry Price
₹26
TrackerBot @trackerbot
Jun 2 3:45 AM

Update
Stoploss Hit
Exit Price
₹24
Like
Reply
Reputation: 3,179 • Jun 1 4:33 AM
Gilead gets conditional approval from India regulator to market remdesivir for COVID-19
The conditional marketing authorisation for remdesivir was granted under the accelerated review process considering the emergency situation and unmet medical needs
Moneycontrol
Like
Reply

Type
Sell
Instrument
CIPLA JUN20 FUT
Entry Price
₹642.1
Price@Trade
₹641.45
Target Price
₹625
Stop Price
₹650
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹173,852.4 approx for 1150 Qty
Status
Stoploss Hit
Exit Price
₹650
Net P&L
-₹9,085 (-5.23%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jun 1 8:59 AM

Update
Trade Entered
Entry Price
₹642.1
TrackerBot @trackerbot
Jun 2 3:17 AM

Update
Stoploss Hit
Exit Price
₹650
Reputation: -13,420 • Jun 1 6:27 AM

Type
Sell
Instrument
CIPLA JUN20 FUT
Entry Price
₹641.8
Price@Trade
₹641.8
Target Price
₹0
Stop Price
₹650
Valid Till
Jun 1, 2020 3:20 AM
Margin
₹176,057.45 approx for 1150 Qty
Status
Exited
Exit Price
₹641.8
Net P&L
₹0 (0%)
Like
Reply (1)
Latest replies
BULL KING @bullking
Jun 1 6:31 AM

Update
Exited
Exit Price
₹641.8
Net P&L
₹0 (0%)
Reputation: -13,420 • Jun 1 4:41 AM

Type
Sell
Instrument
CIPLA JUN20 FUT
Entry Price
₹635.7
Price@Trade
₹635.7
Target Price
₹0
Stop Price
₹650
Valid Till
Jun 1, 2020 3:20 AM
Margin
₹175,799.85 approx for 1150 Qty
Status
Exited
Exit Price
₹641.5
Net P&L
-₹6,670 (-3.79%)
Like
Reply (1)
Latest replies
BULL KING @bullking
Jun 1 6:32 AM

Update
Exited
Exit Price
₹641.5
Net P&L
-₹6,670 (-3.79%)
Reputation: 462 • Jun 1 4:39 AM

Type
Buy
Instrument
CIPLA
Entry Price
₹638
Price@Trade
₹638
Target Price
₹645
Stop Price
₹633
Valid Till
Jun 1, 2020 3:20 AM
Margin
₹63,800 approx for 100 Qty
Status
Validity Over
Exit Price
₹642.8
Net P&L
+₹480 (+0.75%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Jun 1 8:50 AM

Update
Validity Over
Exit Price
₹642.8
Net P&L
+₹480 (+0.75%)
Reputation: 3,179 • Jun 1 4:33 AM
COVID-19 crisis | Remdesivir manufacturers may be allowed to sell only to government for now: Report
Gilead Sciences' experimental drug remdesivir has been found to aid recovery of COVID-19 patients.
Moneycontrol
Like
Reply
A
Reputation: -24,276 • Jun 1 3:21 AM

Type
Buy
Instrument
CIPLA JUN20 640 PE
Entry Price
₹25.65
Price@Trade
₹25.65
Target Price
₹30
Stop Price
₹22.2
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹29,497.5 approx for 1150 Qty
Status
Exited
Exit Price
₹28.5
Net P&L
+₹3,277.5 (+11.11%)
Like
Reply (1)
Latest replies
Atul @atul-Bk5NgsuKI
Jun 1 4:42 AM

Update
Exited
Exit Price
₹28.5
Net P&L
+₹3,277.5 (+11.11%)
V
Reputation: 5,254 • Jun 1 2:50 AM

Type
Buy
Instrument
CIPLA JUN20 FUT
Entry Price
₹645  ₹645.5
Price@Trade
₹639.9
Target Price
₹670
Stop Price
₹623
Valid Till
Jun 2, 2020 3:20 AM  Jun 24, 2020 3:20 AM
Margin
₹176,548 approx for 1150 Qty
Status
Exited
Exit Price
₹648
Net P&L
+₹2,875 (+1.63%)
Like
Reply (4)
Latest replies
Vijay @vijay-rkef8aMU4
Jun 1 2:50 AM

Update
Entry Price Modified
Price @ Update
₹639.95
Original Entry Price
₹645
New Entry Price
645.5
TrackerBot @trackerbot
Jun 1 2:55 AM

Update
Trade Entered
Entry Price
645.5
Vijay @vijay-rkef8aMU4
Jun 2 3:06 AM

Update
Time Extended
Price @ Update
₹644.8
Original Time
Jun 2, 2020 3:20 AM
New Time
Jun 24, 2020 3:20 AM
Vijay @vijay-rkef8aMU4
Jun 3 3:40 AM

Update
Exited
Exit Price
₹648
Net P&L
+₹2,875 (+1.63%)

Type
Buy
Instrument
CIPLA
Entry Price
₹643.5
Price@Trade
₹643.5
Target Price
₹2,000
Stop Price
₹500
Valid Till
May 28, 2021 3:20 AM
Margin
₹997,425 approx for 1550 Qty
Status
Active
Like
Reply
Reputation: 354 • May 29 4:42 AM

Type
Sell
Instrument
CIPLA JUN20 FUT
Entry Price
₹640
Price@Trade
₹640.05
Target Price
₹620
Stop Price
₹652
Valid Till
Jun 5, 2020 3:20 AM
Margin
₹167,133.35 approx for 1150 Qty
Status
Exited
Exit Price
₹638.35
Net P&L
+₹1,897.5 (+1.14%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
May 29 4:43 AM

Update
Trade Entered
Entry Price
₹640
SharePol @SharePol
May 29 7:47 AM

Update
Exited
Exit Price
₹638.35
Net P&L
+₹1,897.5 (+1.14%)
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • CIPLA - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization42,645.7
    Enterprise Value42,471.14
    Price to Earnings29.77
    Price to Book Value2.7
    Return on Capital Employed0.13
    Return on Equity0.1
    Face Value2
    Dividend Yield0.01
  • CIPLA - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    18-May-20Nirmal BangAccumulate575
    16-May-20HDFC SecuritiesBuy655
    16-May-20Prabhudas LilladherReduce542
    9-Apr-20HDFC SecuritiesBuy600
    6-Feb-20Motilal OswalNeutral490
    CIPLA Brokerage Price Target
  • CIPLA Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jun 5665669.75649650.9
    Jun 4643664.8642.5660.55
    Jun 3646.85649.5635.3641.2
    Jun 2644.9658.65636637.6
    Jun 1649652.6634.55642.5
  • CIPLA Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹615.02
    30 Day Moving Average₹608.99
    50 Day Moving Average₹558.37
    100 Day Moving Average₹502.78
    200 Day Moving Average₹482.97
  • CIPLA - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue11,39010,974.580.04
    Operating Profit2,1181,596.260.33
    Profit Before Tax1,9111,186.940.61
    Net Income1,469974.940.51
  • CIPLA - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds15,78214,1140.12
    Total Liabilities2,6373,497-0.25
    Total Assets18,41917,6100.05
  • CIPLA - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,1172,205.56-0.49
    Cash from Investing Activity-593-1,191.75-0.5
    Cash from Financing Activity-351-1,008.97-0.65
    Net Cash Flow1734.8434.74
  • CIPLA - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.080.06
    Return on Equity0.10.08
    Return on Capital Employed0.130.09
  • CIPLA - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.12
    3 Year CAGR Growth in Operating Profit0.08
    3 Year CAGR Growth in EBIDTA0.16
    3 Year CAGR Growth in Net Income0.24
    3 Yr CAGR Growth - Diluted EPS0.24
  • CIPLA - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.39
    5 Year CAGR Growth in Operating ProfitNA
    5 Year CAGR Growth in EBIDTA0.05
    5 Year CAGR Growth in Net Income-0.03
    3 Yr CAGR Growth - Diluted EPS-0.03
  • CIPLA - Recent News

    keyboard_arrow_down
    NewsBot
    Today 7:48 AM
    Monsoon to bring relief amid COVID-19 pain; 9 stocks that could benefit
    Moneycontrol
    NewsBot
    Today 4:51 AM
    Share market update: 29 stocks hit 52-week highs on NSE
    The Economic Times
    NewsBot
    Yesterday 2:01 AM
    Indian licensees free to price Remdesivir: Gilead
    The Economic Times
    NewsBot
    Jun 3 5:51 AM
    Share market update: Pharma shares climb; Dr Reddy's Labs gains 2%
    The Economic Times
    NewsBot
    Jun 1 4:33 AM
    Gilead gets conditional approval from India regulator to market remdesivir for COVID-19
    Moneycontrol
    NewsBot
    Jun 1 4:33 AM
    COVID-19 crisis | Remdesivir manufacturers may be allowed to sell only to government for now: Report
    Moneycontrol
    NewsBot
    May 28 8:48 AM
    Buy Cipla target of Rs 738: Anand Rathi
    Moneycontrol
    NewsBot
    May 26 6:53 AM
    F&O expiry to keep market volatile; 5 stocks where experts see 8-16% upside
    Moneycontrol
    NewsBot
    May 21 3:03 AM
    Cipla Consolidated March 2020 Net Sales at Rs 4,376.19 crore, down 0.63% Y-o-Y
    Moneycontrol
    NewsBot
    May 21 2:23 AM
    Looking for momentum plays? Top 4 stocks which could give over 15% returns in 1-3 months
    Moneycontrol
  • CIPLA - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
  • CIPLA - More Information

    keyboard_arrow_down

    Cipla Ltd:
    Cipla Limited, along with its multiple subsidiaries, is responsible for the manufacture and sale of pharmaceutical goods in India. It provides a variety of formulations and active pharmaceutical ingredients in various aspects like urology, ophthalmology, malaria, oncology, neurosciences, women’s and children’s health, hepatitis, critical care, osteoporosis, and infectious diseases.
    The company provides multiple inhalation therapy devices like nasal sprays, metered-dose inhalers, accessory devices, dry powder inhalers, and nebulizers. Apart from manufacturing and selling these products in India, it also exports to Russia, the Middle East, Asia, Australia, New Zealand, and Latin America and other regions internationally.
    On 17th of August in 1935, Cipla got registered as a public limited with a capital of Rs. 6 lakh and is a Mumbai based Company in India. During the Second World War, when the drug supplies were topped in 1941, the company started to produce fine chemicals. At this point, Cipla dedicated its facilities to provide a variety of ingenious drugs.
    About Company Information:
    Within the next two decades after the inception of the Second World War, in 1960, the company started its operations in Vikhroli, Mumbai. This was their second plant. At this unit, they produced fine chemicals related to natural products. Ampicillin was manufactured for the first time in the country in 1968 by Cipla. To cultivate medicinal plants, the company then started their Agricultural Research Division, located in Bangalore, in the year 1972.
    In 1982, the company started operating in its fourth manufacturing unit located in Patalganga, Maharashtra. The company collaborated with the National Chemical Laboratory in Pune, in the year 1984 to produce anti-cancer drugs like vincristine and vinblastine. Collaborating with Indian Institute of Chemical Technology, in 1991, a drug considered to be a breakthrough in chemotherapy, named etoposide was launched by the company. Later on, an antiretroviral drug called zidovudine was also manufactured by the company in association with Indian Institute of Chemical Technology.
    Nevirapine, an antiretroviral drug used to stop AIDS transmission in a child from a mother, was launched by the company in 1999. Cipla was the first company, outside of Europe and U.S.A, which began CFC-free-inhalers, in the year 2000. In February in 2007, the company allied with the Drugs for Neglected Diseases Initiative for developing a new anti-malarial drug. This was a worldwide initiative taken by the company with a non-profit organization like DNDI.
    In April of 2010, the company started its operations for commercial production of a variety of pharmaceutical formulations at their SEZ project in Indore, MP. On the 21st of July, 2012, Cipla revealed that they were to collaborate with DNDi (a non-profit R&D organization) for developing an improved form of antiretroviral (ARV) combo therapy which will specifically treat kids affected by HIV/AIDS.
    On the 17th of April, 2013, Cipla announced that they would be the first to launch a biosimilar of Etanercept in the country which will be targeted to treat rheumatic disorders. On the 20th of February in 2014, Cipla announced their alliance with MSD which would give them a non-exclusive license using which they would sell raltegravir 400mg tablet (a drug from MSD) along with marketing and distribution of the drug but down under a different brand name.
    In February 2015, Cipla revealed to have been awarded a Global Fund ARV Tender which is worth USD 188.95 million for developing antiretroviral drugs.
    On the 12th of October, 2016, Cipla announced the formal closing of US FDA inspection that was conducted in July-August in the year 2015. Cipla was given the establishment inspection report by the FDA, and it was held AT THE Indore Unit of the company. On the 30th of November, 2017, Cipla publicized the fact that the company had received approval from the World Health Organization (WHO) for a product name Q-TIB, which is essentially a combination of novel fixed-dose within a single tablet form. This was the first combination to ever exist in the world.
    How Cipla Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cipla Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cipla Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020